Search

In this study, 37 derivatives of phorbol esters were synthesized and their anti-HIV-1 activities evaluated, building upon our previous synthesis of 51 phorbol derivatives. 12-Para-electron-acceptor-trans-cinnamoyl-13-decanoyl phorbol derivatives stood out, demonstrating remarkable anti-HIV-1 activities and inhibitory effects on syncytia formation. These derivatives exhibited a higher safety index compared with the positive control drug. Among them, 12-(trans-4-fluorocinnamoyl)-13-decanoyl phorbol, designated as compound 3c, exhibited the most potent anti-HIV-1 activity (EC 50 2.9 nmol·L -1 , CC 50 /EC 50 11 117.24) and significantly inhibited the formation of syncytium (EC 50 7.0 nmol·L -1 , CC 50 /EC 50 4891.43). Moreover, compound 3c is hypothesized to act both as an HIV-1 entry inhibitor and as an HIV-1 reverse transcriptase inhibitor. Isothermal titration calorimetry and molecular docking studies indicated that compound 3c may also function as a natural activator of protein kinase C (PKC). Therefore, compound 3c emerges as a potential candidate for developing new anti-HIV drugs., (Copyright © 2024 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.)

Sulfated polymannuronate (SPMG), a novel anti-AIDS drug candidate, combats HIV-1 infection mainly by binding to gp120 protein with high affinity. To explore the structural basis of this anti-HIV-1 action, size-defined oligosaccharides were prepared by semi-synthesis or separated from native SPMG. In this study, a series of homogeneously sized SPMG fragments are evaluated for their capacity to bind rgp120 using surface plasmon resonance (SPR) analysis. The minimum SPMG fragment size that interacts with rgp120 is a hexasaccharide. Additionally, binding capacity increases with the molecular size of oligosaccharides, with the affinity of large fragments (> or = 15-16 saccharides) approaching that of full-sized SPMG. Competitive inhibition and stoichiometric analyses disclose that SPMG oligos bind to multiple binding sites on gp120. Sugar chains longer than 15-16 saccharide residues (SPMG) display multivalent interactions, with one sugar chain binding to two or three gp120 molecules. Consistent with binding data, a positive correlation exists between the size of SPMG oligosaccharides and their anti-HIV activity. The octasaccharide is established to be the minimal active fragment inhibiting syncytium formation and lowering the P24 core antigen level in HIV-IIIB-infected CEM cells. Alternatively, about 50% anti-HIV activity was observed for 15-16 saccharides, whereas a 19-20-saccharide fragment displayed anti-HIV activity equivalent to native SPMG. The structures of the unique minimum hexasaccharide specifically recognized by gp120 and the minimum octasaccharide combating HIV-IIIB infection were representatively structured as [ManA (2s)beta1-4 ManA(2s/3s)]n.

Thesmall molecule fusion inhibitors N-(4-carboxy-3-hydroxyphenyl)-2,5-dimethylpyrrole(NB-2) and N-(3-carboxy-4-hydroxyphenyl)-2,5-dimethylpyrrole(A12) target a hydrophobic pocket of HIV-1 gp41 and havemoderate anti-HIV-1 activity. In this paper, we report the design,synthesis, and structure–activity relationship of a group ofhybrid molecules in which the pocket-binding domain segment of theC34 peptide was replaced with NB-2 and A12derivatives.In addition, the synergistic effect between the small molecule andpeptide moieties was analyzed, and lead compounds with a novel scaffoldwere discovered. We found that either the nonpeptide or peptide partalone showed weak activity against HIV-1-mediated cell–cellfusion, but the conjugates properly generated a strong synergisticeffect. Among them, conjugates Aoc−βAla–P26 andNoc−βAla–P26 exhibited a low nanomolar IC50in the cell–cell fusion assay and effectively inhibitedT20-sensitive and -resistant HIV-1 strains. Furthermore, the new moleculesexhibited better stability against proteinase K digestion than T20and C34. [ABSTRACT FROM AUTHOR]